Research programme: heat shock protein 90 modulators - Evotec AG/GenextraAlternative Names: HSP90-targeted compounds - Evotec/Genextra
Latest Information Update: 07 Jul 2009
At a glance
- Originator Evotec AG; Genextra
- Class Small molecules
- Mechanism of Action Heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Jul 2009 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 07 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 07 Jul 2009 Discontinued - Preclinical for Cancer in Germany (unspecified route)